Brandes International ETF (BINV)
CBOE: BINV
· Real-Time Price · USD
38.21
0.14 (0.37%)
At close: Sep 26, 2025, 3:59 PM
0.37% (1D)
| Bid | 35.8 |
| Market Cap | 281.08M |
| AUM | 208.51M |
| NAV | 34.3 |
| EPS (ttm) | 2.26 |
| PE Ratio (ttm) | 16.88 |
| Shares Out | 7.36M |
| Inception Date | Oct 9, 2023 |
| Ask | 40.39 |
| Volume | 39,553 |
| Open | 38.15 |
| Previous Close | 38.07 |
| Day's Range | 38.06 - 38.22 |
| 52-Week Range | 28.93 - 38.66 |
| Holdings | 67 |
| Expense Ratio | 0.70% |
About BINV
The fund is an actively managed exchange-traded fund (“ETF”) that seeks to attain its investment objective by investing primarily in equity securities of foreign companies. The fund typically invests in foreign companies with market capitalizations (market value of publicly traded equity securities) greater than $5 billion at the time of purchase.
Asset Class Equity
Ticker Symbol BINV
Inception Date Oct 9, 2023
Provider Other
Website Fund Home Page
Exchange CBOE
Top Sectors
| Sector | Weight % |
|---|---|
| Consumer Defensive | 22.42% |
| Healthcare | 17.42% |
| Consumer Cyclical | 13.75% |
| Financial Services | 9.84% |
| Technology | 9.48% |
Top 10 Holdings 24.46% of assets
| Name | Symbol | Weight |
|---|---|---|
| Alibaba Group Holdin... | BABA | 3.43% |
| Sanofi | SNYNF | 2.80% |
| Gsk Plc | GSK | 2.59% |
| Kering Sa | PPRUY | 2.59% |
| The Swatch Group Ag | SWGNF | 2.53% |
| Petróleo Brasileiro ... | PBR-A | 2.46% |
| Ubs Group Ag | UBS | 2.04% |
| Carrefour S.a. | CRERF | 2.02% |
| Henkel Ag & Co. Kgaa | HELKF | 2.01% |
| Koninklijke Philips ... | PHG | 1.99% |
Dividends Dividend Yield 2.16%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Jun 27, 2025 | $0.4950 | Jun 30, 2025 |
| Mar 28, 2025 | $0.0180 | Mar 31, 2025 |
| Dec 30, 2024 | $0.1578 | Dec 31, 2024 |
| Sep 27, 2024 | $0.1003 | Sep 30, 2024 |
| Jun 27, 2024 | $0.4288 | Jun 28, 2024 |
7 months ago · accessnewswire.com
BioInvent International AB: Year-End Report January 1 - December 31, 2024LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical program...